Consistent with the dose-dependent and prolonged exposure in xenograft tumors, oral administration of RMC-6236 led to dose-dependent and durable suppression of RAS pathway signaling as measured by human DUSP6 (a RAS/MAPK pathway transcriptional target) mRNA expression levels in tumor lysates (Fig. 2B). Here, DUSP6 is linked to neoplasm.